Safety of soy-derived phosphatidylserine in elderly people.
Study Design
- Tipo de estudio
- Randomized Controlled Trial
- Tamaño de muestra
- 120
- Población
- Elderly individuals (mean age 70)
- Duración
- 12 weeks
- Intervención
- Safety of soy-derived phosphatidylserine in elderly people. Soy-derived phosphatidylserine 300mg or 600mg/day
- Comparador
- Placebo
- Resultado primario
- Safety and tolerability in elderly
- Dirección del efecto
- Neutral
- Riesgo de sesgo
- Low
Abstract
Phosphatidylserine (PS) is a phospholipid which has been claimed to enhance neuronal membrane function, and can be derived from several sources. Earlier studies used brain cortex derived PS, of which the human tolerability of 300mg daily in 130 patients has been shown. The human tolerability of PS derived from soybean has not been reported, although it is widely sold as a nutritional supplement which may improve cognitive function in the elderly. We report the results of a study of the safety of two dosages of soy-phosphatidylserine (S-PS) in elderly. Subjects were 120 elderly of both sexes who fulfilled the more stringent criteria for age-associated memory impairment; some also fulfilled the criteria for age-associated cognitive decline. Subjects were allocated at random to one of the three treatment groups: placebo, 300 or 600 mg S-PS daily. Standard biochemical and hematological safety parameters, blood pressure, heart rate and adverse events were assessed at baseline, after 6 and 12 weeks of treatment. No significant differences were found in any of the outcome variables between the treatment groups after Bonferonni-Holme correction. In conclusion, soy derived PS is a safe nutritional supplement for older persons if taken up to a dosage of 200 mg three times daily.
TL;DR
Soy derived PS is a safe nutritional supplement for older persons if taken up to a dosage of 200 mg three times daily, although it is widely sold as a nutritional supplement which may improve cognitive function in the elderly.
Used In Evidence Reviews
Similar Papers
Cellular and molecular life sciences : CMLS · 2005
Surface exposure of phosphatidylserine in pathological cells.
Molecular medicine (Cambridge, Mass.) · 2011
Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease.
Cell · 1983
Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site?
Journal of Alzheimer's disease : JAD · 2012
Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease.
Current opinion in hematology · 2000
Oxidation and erythrocyte senescence.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2006